The aforementioned protocol paved the way for the creation of a representative collection of well-characterized breast cancer organoids that matched the histopathology, ER, PR, and HER2 status of the tumor of origin, as well as populated the main gene-expression-based classification categories [18]. This evidence concerns the gene ERBB2 and breast carcinoma.